Fresh from a meeting with drug makers, advocacy groups, and government agencies, World Health Organization officials say they are gradually moving closer to a framework for so-called fair pricing for prescription medicines.
Although recommendations are not yet forthcoming, the latest meeting builds on efforts that began a year ago and, at the time, identified several key issues to be addressed. A report by an informal advisory group last fall named transparency in pricing and research and development costs; the right of governments to issue compulsory licenses; manipulation of orphan drug designations; medicine shortages; and the merits of value-based pricing.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
When the industry argument first stresses the equivalent of ‘fraud and abuse,’ I’m not very hopeful. Then again, we have to start somewhere.